XCath Secures $30 Million to Revolutionize Neuro-Endovascular Robotics
March 13, 2026, 11:26 am
XCath secured $30 million in Series C funding. This boosts its neuro-endovascular surgical robotics development. The Iris system targets complex brain aneurysms and stroke treatment. It uniquely achieves intracranial navigation. This innovation promises to expand global access to advanced neurovascular care, making life-saving procedures more widely available.
XCath, a leading medical device innovator, announced a substantial $30 million Series C funding round. This significant capital infusion propels the company's mission. It will accelerate development and eventual commercialization of its advanced endovascular surgical robot. The new financing brings XCath’s total investment to $92 million since its 2017 inception. This highlights strong investor confidence.
The Series C round saw co-leadership from Crescent Enterprises. Dr. Fred Moll, XCath’s esteemed board chairman, also co-led the investment. This funding empowers XCath. It supports ongoing efforts to refine its robotic platform. Critical clinical telerobotic mechanical thrombectomy trials are now in focus. This procedure offers vital stroke treatment. It could dramatically expand access to specialized neurovascular care worldwide.
XCath is based in Houston, Texas. It also operates a campus in Pangyo, South Korea. The company’s flagship technology is the Iris robotic system. This system is purpose-built for neurointerventional procedures. These interventions involve the delicate blood vessels of the brain. The Iris system represents a significant leap in neurovascular robotics.
Groundbreaking clinical milestones have already been achieved. In November 2025, the Iris system facilitated its first-in-human procedures. These treated patients suffering from complex brain aneurysms. Dr. Vitor Mendes Pereira performed these procedures. They took place at The Panama Clinic in Panama City. This marked a historic moment in surgical robotics. It was only the second time a surgical robot had performed an intracranial neurovascular intervention.
XCath’s Iris platform stands alone in the field. It is the only endovascular robotic system currently in development. It has achieved intracranial navigation. It also delivers neurointerventional treatment capabilities. This distinction underscores its unique technological prowess. The system further demonstrated robotic manipulation of three devices during an intracranial neurovascular procedure. This showcases its advanced dexterity.
Another key advantage is its operational flexibility. The Iris system functions using standard monoplane imaging equipment. This feature is crucial. It supports broader adoption in diverse clinical settings. Many hospitals already possess this common imaging technology. Such compatibility removes significant barriers to implementation. It promises wider availability of advanced care.
Neurovascular diseases represent a critical global health challenge. Stroke, in particular, demands urgent and precise intervention. Current access to specialized care remains geographically limited. XCath directly addresses this disparity. Its robotic technology aims to democratize access. It seeks to ensure that a patient's location does not dictate their survival chances.
The potential for telerobotics further enhances this vision. Imagine a stroke specialist guiding an Iris robot remotely. This could deliver life-saving mechanical thrombectomy in underserved regions. Such a future is becoming tangible through XCath’s innovations. This expands the reach of expert neurovascular treatment exponentially. It promises significant improvements in patient outcomes.
The market opportunity for neuro-endovascular robotics is vast. Neurovascular diseases carry substantial financial and human costs. Positive reimbursement dynamics drive demand from health systems. XCath positions itself strongly within this burgeoning sector. Its disciplined capital deployment strategies fortify its market leadership aspirations.
The company's leadership team is robust. It combines seasoned physicians, entrepreneurs, and engineers. This collective expertise focuses on a singular mission. It aims to address critical unmet global healthcare needs. Robotic surgery continues its expansion. XCath leads the charge in this highly specialized and impactful domain.
XCath's endovascular robotic system is still under development. It has not yet received commercial distribution clearance in any country. However, its progress is undeniable. The recent funding validates its trajectory. It reinforces the belief in its ability to transform neurovascular care. The future of precise, accessible brain surgery is rapidly approaching. XCath is at its forefront. This innovation will redefine patient care in the most complex medical scenarios.
XCath, a leading medical device innovator, announced a substantial $30 million Series C funding round. This significant capital infusion propels the company's mission. It will accelerate development and eventual commercialization of its advanced endovascular surgical robot. The new financing brings XCath’s total investment to $92 million since its 2017 inception. This highlights strong investor confidence.
The Series C round saw co-leadership from Crescent Enterprises. Dr. Fred Moll, XCath’s esteemed board chairman, also co-led the investment. This funding empowers XCath. It supports ongoing efforts to refine its robotic platform. Critical clinical telerobotic mechanical thrombectomy trials are now in focus. This procedure offers vital stroke treatment. It could dramatically expand access to specialized neurovascular care worldwide.
XCath is based in Houston, Texas. It also operates a campus in Pangyo, South Korea. The company’s flagship technology is the Iris robotic system. This system is purpose-built for neurointerventional procedures. These interventions involve the delicate blood vessels of the brain. The Iris system represents a significant leap in neurovascular robotics.
Groundbreaking clinical milestones have already been achieved. In November 2025, the Iris system facilitated its first-in-human procedures. These treated patients suffering from complex brain aneurysms. Dr. Vitor Mendes Pereira performed these procedures. They took place at The Panama Clinic in Panama City. This marked a historic moment in surgical robotics. It was only the second time a surgical robot had performed an intracranial neurovascular intervention.
XCath’s Iris platform stands alone in the field. It is the only endovascular robotic system currently in development. It has achieved intracranial navigation. It also delivers neurointerventional treatment capabilities. This distinction underscores its unique technological prowess. The system further demonstrated robotic manipulation of three devices during an intracranial neurovascular procedure. This showcases its advanced dexterity.
Another key advantage is its operational flexibility. The Iris system functions using standard monoplane imaging equipment. This feature is crucial. It supports broader adoption in diverse clinical settings. Many hospitals already possess this common imaging technology. Such compatibility removes significant barriers to implementation. It promises wider availability of advanced care.
Neurovascular diseases represent a critical global health challenge. Stroke, in particular, demands urgent and precise intervention. Current access to specialized care remains geographically limited. XCath directly addresses this disparity. Its robotic technology aims to democratize access. It seeks to ensure that a patient's location does not dictate their survival chances.
The potential for telerobotics further enhances this vision. Imagine a stroke specialist guiding an Iris robot remotely. This could deliver life-saving mechanical thrombectomy in underserved regions. Such a future is becoming tangible through XCath’s innovations. This expands the reach of expert neurovascular treatment exponentially. It promises significant improvements in patient outcomes.
The market opportunity for neuro-endovascular robotics is vast. Neurovascular diseases carry substantial financial and human costs. Positive reimbursement dynamics drive demand from health systems. XCath positions itself strongly within this burgeoning sector. Its disciplined capital deployment strategies fortify its market leadership aspirations.
The company's leadership team is robust. It combines seasoned physicians, entrepreneurs, and engineers. This collective expertise focuses on a singular mission. It aims to address critical unmet global healthcare needs. Robotic surgery continues its expansion. XCath leads the charge in this highly specialized and impactful domain.
XCath's endovascular robotic system is still under development. It has not yet received commercial distribution clearance in any country. However, its progress is undeniable. The recent funding validates its trajectory. It reinforces the belief in its ability to transform neurovascular care. The future of precise, accessible brain surgery is rapidly approaching. XCath is at its forefront. This innovation will redefine patient care in the most complex medical scenarios.